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1
2
3 47 To the Editor:
4
5 48 Despite recent advances in diagnostic methods, diagnosis of primary ciliary dyskinesia (PCD)
6 49 remains complex. We need a combination of different diagnostic tests, and all have their limitations
8 50 [1]. In 2009, the first European Respiratory Society Task Force (ERS TF) on PCD in children
9
10 51 published recommendations [2], suggesting that: 1) Nasal nitric oxide (nNO) should be measured
11 52 to screen for PCD in patients aged ≥5 years [3]; and 2) video microscopy (VM) analysis of ciliary
12
13 53 beat pattern and frequency [4] plus electron microscopy (EM) [5] should be the key confirmatory
14 54 diagnostic tests. Genetic testing was not recommended as part of the initial diagnostic testing, but
15
16    55 as additional test for inconclusive cases. The recommended test combination was nNO, VM and
17
18    56 EM for patients aged ≥ 5 years and VM plus EM for younger patients.
19
20 57 In 2017, a second ERS TF on PCD diagnosis revised the accumulated literature and published
21 58 evidence-based guidelines [6]. Although evidence-based guidelines have become the norm in
22
23    59 research, their practical implementation can be challenging [7]. We wanted to assess whether the
24
25 60 2009 diagnostic recommendations had been implemented and how diagnosis of PCD changed in
26 61 Europe over time. This knowledge will help to improve implementation of the new guidelines.
27
28    
62 We analysed data from the international PCD cohort (iPCD) (details are published elsewhere [8]).
29
30    63 By May 2018, iPCD included data on 3733 patients from 26 centres in 21 countries. For this study,
31
32 64 we included all datasets from European centres that tested patients with PCD, both before and
33 65 after 2009, and had complete information on nNO, EM and VM testing. We excluded patients in
34
35    66 whom diagnosis was based only on clinical presentation, patients with unknown dates of testing.
36
37    67 We included 2108 patients from 16 centres (11 European countries) (Belgium, Cyprus, Czech
38
39 68 Republic, France, Germany, Italy, Norway, Poland, Switzerland, Turkey and United Kingdom); 51%
40 69 were male, 818 patients (39%) had been diagnosed before and 1290 after 2009. All three
41
42 70 recommended tests were available in all countries, with the exception of Norway where VM testing
43 71 was not available neither before nor after 2009.
44
45
46 72 Based on the 2009 recommendations, we only considered nNO measurements in patients aged 5
47 73 years or older [2]. We considered the nNO test as positive when nNO was below 77 nL·min−1
48
49 74 [9,10]. VM had been performed with different techniques over time, with high speed video analysis
50 75 being the most commonly used technique in recent years. We classified VM and EM results as
51
52 76 pathological based on information provided by the centres on the beat frequency, beat pattern and
53 cilia ultrastructure. For each patient, we defined the calendar year of diagnosis based on the date
54
55    78 of the earliest positive test result. We then assessed whether there was a change over time in the
56
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77
57 79 proportion of diagnosed patients who had received a) the recommended test combination; b) any
58 80 single test. We compared the proportion of patients with the recommended test combination (VM
59
60
5
5
5
6
5
7
5
1
1
2
3 81 and EM for patients aged <5 years and nNO, VM and EM for older patients) for the two time
4
5 82 periods, before and after 2009. We used R version 3.1.2 for all analyses.
6
7 83 Recommended test combination: Overall, we found no significant trend over time in the use of
8
9 84 the test combination. The three tests had been used in 54% of patients diagnosed before 2009 and
10 85 in 57% after 2009 (p=0.15) (Figure 1). In preschool children the proportion diagnosed with the
11
12 86 recommended combination was 72% before and 75% (p=0.47) after 2009; in older patients it
13 87 increased from 46% to 52% (p=0.03). Results differed between countries. Few countries (e.g.
14
15 88 Belgium, Cyprus) combined all 3 tests already before 2009 for most patients and continued to do
16 89 so after 2009. In Germany, the UK and the Czech Republic, the combined use of all 3 tests was
17
18    90 common already before 2009 but increased even more after 2009, with almost ¾ of the patients
19
20 91 tested according to recommendations. The remaining countries (Turkey, Switzerland, Italy, France
21 92 and Poland) showed little or no change over time. In these countries, less than half of the patients,
22
23    93 were tested with all 3 approaches even in the later period.
24
25    94 Nasal NO testing increased overall from 63% before 2009 to 84% afterwards (p<0.001). This
26
27 95 increase was seen in most countries (Figure 1). After 2009, nNO was measured in over ¾ of
28 96 patients in all countries, except in Czech Republic (65%), Italy (70%) and UK (77%).
29
30 97 Electron microscopy was frequently performed before 2009 (97%) but decreased to 80%
31 98 (p<0.001) in the later period. Its use became less common in Poland (79% to 69%), Switzerland
32
33 99 (88% to 62%) and Turkey (100% to 18%), in all other countries it remained stable or increased
34 100 after 2009. Video microscopy analysis increased overall from 76% to 87% (p<0.001). This was
36 101 mainly because the use of VM for PCD diagnosis increased considerably in Italy (36% to 69%) and
37
38 102 Turkey (25% to 88%). In most countries, its use remained stable, while in Switzerland (50% to
39 103 21%) it decreased substantially.
40
41 
104 This is the first multi-national study that compared diagnostic testing in PCD patients between
43 105 countries and over time. Although a large number of countries contribute to iPCD, some had to be
44
45 106 excluded for this analysis as they only contributed patients diagnosed after 2009 to the iPCD
46 107 cohort. Thus, our study describes how the consensus recommendations were implemented in 11
47
48 108 countries. They are not representative for all European countries, but only for those with
49 109 established PCD diagnostic protocols. In this analysis we included both children and adults.
50
51 110 However when we limited the analysis to children only, for whom the 2009 recommendations were
52
53 111 intended, results remained similar.
54
55 112 Our results suggest that the implementation of the recommended diagnostic combination of nNO,
56 113 EM and VM testing after the 2009 consensus statement remained low. This reflects the complex
57
58 114 nature of PCD diagnostics and the regional resources. Many countries continued to perform only
59
60 115 one or two of the recommended tests. There are several explanations for this observation. First,
3
5
4
2
1
2
3    116 the availability of local resources could have led to the development of alternative diagnostic
4
5 117 pathways, which may have been most appropriate for the local situation at that time. All PCD
6 118 diagnostic tests need specialised expensive equipment and personnel experienced in analysis of
7
8 119 VM and EM results, which are not available in all settings. Limited resources or decentralised
9 120 healthcare might not have allowed to set up diagnostic centres with scientists experienced in all
11 121 methods. For countries with limited resources cost-effective alternatives for diagnostic testing have
12
13 122 been suggested, which might provide an acceptable diagnostic accuracy [11]. Second, since 2009
14 123 the use of other methods including genetic testing [12,13] and immunofluorescence microscopy
15
16 124 [14,15] became more widespread. These newer methods might have been used instead of the
17 125 recommended tests in some centres. Lastly, the lack of sufficient evidence supporting the use of
18
19 126 some diagnostic tests in 2009 might have prevented some countries to implement the full set of
20
21 127 recommended tests but let them to develop their own diagnostic algorithms. We found
22 128 considerable heterogeneity between countries in the use of the three tests. Overall, countries with
23
24 129 low prior use of nNO showed improvement and nNO is now used in most patients aged ≥ 5 years
25 130 suspected for PCD. For the proportion of patients who were still not tested after 2009, we
26
27 131 speculate that nNO was not performed as a screening test, and the primary investigators chose to
28 132 do directly one or both of the other tests. In this case, if the diagnosis was already established
29
30 133 based on the results of the other tests, the patients might not have been invited posthoc to perform
31
32 134 also nNO measurement. This would be in line with the recommendations. We found that use of EM
33 135 analysis decreased, and VM increased, suggesting that there might be a shift from EM to VM
34
35 136 overall. Possible reasons are the realization that a significant proportion of patients have normal
36 137 EM findings [16] and the high costs of EM analysis combined with an increased availability of VM,
37
38 138 so that only patients with inconclusive VM results were referred for EM testing. The overall
39
40 139 changes in use of VM and EM analyses were strongly affected by the marked increase in VM and
41 140 decrease in EM analysis in Turkish patients. This shift is explained by the development of a new
42
43 141 PCD centre, which uses VM more and EM less frequently.
44
45 142 The 2009 PCD diagnostic consensus is a typical example of how difficult it is to implement
46
47 143 guidelines in clinical practice. Even though the recommendations were widely presented in
48 144 scientific conferences and meetings, improving knowledge is not sufficient to change daily
49
50 145 practices. A synthesis of systematic reviews on clinical guideline implementation strategies showed
51 146 that passive dissemination was an ineffective measure and that implementation strategies should
52
53 147 be multifaceted, and actively engage clinicians throughout the process [7]. In the case of PCD
54 148 diagnosis, implementation is further hindered by fragmentation of national diagnostic services in
55
56 149 many centres and the cost of diagnostic equipment. In our study, countries with limited resources
57
58 150 (e.g. Poland, Turkey) or decentralised diagnosis (e.g. France, Italy, Switzerland) performed the
59 151 recommended test combination less frequently, than countries with more resources (e.g. Germany,
60
152 Belgium, UK) or established centralised PCD diagnosis (e.g. Cyprus, UK). National and multi-
1
0
1
2
3    153 national collaborations, such as the European Reference Network for respiratory diseases (ERN-
4
5 154 Lung; https://ern-lung.eu/) might play an important role, in the future to facilitate centralised
6 155 diagnosis and standardised patient care. With the further development and improvement of
7
8 156 diagnostic tests for PCD and with new centres emerging, that might lack the necessary expertise,
9 157 there is an increased need for national and international collaboration in PCD diagnostic testing.
11
12 158 Overall, we found a low adherence to the 2009 consensus recommendations mainly due to the
13 159 decrease in use of EM analysis in some countries. This resulted in low use of the recommended
14
15 160 test combination. To further improve PCD diagnosis, we must be more diligent and engaging in
16 161 implementing the new evidence-based guidelines published in 2017, putting more emphasis on
17
18 162 establishing specialised diagnostic centres and close international collaboration.
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